Mike Rusinko is a creative business executive who has worked for and with some of the premier brands in the world. In his nearly thirty years with Accenture, Rusinko has led and managed regional and global efforts that have focused on driving revenue growth by transforming business practices and building enduring relationships. Rusinko brings the best practices of a globally renowned professional services firm and combines that with the heart of an entrepreneur. The combination results in creative and practical solutions to complex business challenges across a wide variety of industries. Rusinko’s engaged management style is a large reason for his success as are his commitment to team and professionalism. These attributes have resulted in his ability to work across the expanse of Accenture’s extensive business offerings, global operations and client base.
Dr. Largaespada is an authority on mouse genetics, gene modification, cancer genes, and disease models. His outstanding background was integral to the founding of B-MoGen Biotechnologies, Inc. He spent five years as a postdoctoral fellow in Frederick, Maryland at the National Cancer Institute working with world-renowned geneticists Dr. Nancy Jenkins and Dr. Neal Copeland, where the Leukemia and Lymphoma Society of America awarded him a postdoctoral fellowship. He is currently a Full Professor in the Department of Pediatrics and the Department of Genetics, Cell Biology and Development at the University of Minnesota.
Jeff is a senior executive with a proven track record at profitably growing emerging companies and business divisions. His experience developing businesses to 1st and 2nd market positions, raising over $3.2 million for prior start-ups, and leading start-to-finish M&A transactions from $4 million to over $2 billion. Jeff comes to B-MoGen after serving for two years as COO of a cGMP cellular therapy company where in his first year he completed a turnaround of their CDMO services to its’ first ever profitable status. As the business leader in B-MoGen Biotechnologies, Jeff aims to enable the company to become an industry leader in gene editing.